Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold

  • Bioorg Med Chem Lett. 2021 Sep 1;47:128215. doi: 10.1016/j.bmcl.2021.128215.
Qun Niu  1 ,  Hongguang Deng  1 ,  Zhenwei Zhang  1 ,  Qinhao Xu  1 ,  Shenglin Luan  2 ,  Min Huang  1 ,  Dan Liu  1 ,  Linxiang Zhao  3
Affiliations
  • 1. Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
  • 2. Shenzhen Bay Laboratory, Shenzhen, China.
  • 3. Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: [email protected].
PMID: 34153472 DOI: 10.1016/j.bmcl.2021.128215
Abstract

The anti-apoptotic protein inhibitors of the B cell lymphoma 2 (Bcl-2) family have been developed as new Anticancer therapies. Numerous studies illustrated the great potential in the development of dual Bcl-2/myeloid cell leukemia 1 (Mcl-1) inhibitors. Herein, we reported a series of Bcl-2/Mcl-1 inhibitors that optimized from a hit compound 1 via structure-based rational design. The biological evaluation suggested that most compounds exhibited potent binding affinities at submicromolar to both Bcl-2 and Mcl-1 without any Bcl-xL binding affinities, especially compound 9o, with a Ki value of 0.07 μM to Mcl-1 and 0.66 μM to Bcl-2, that has great potential for developing dual inhibitors targeting Bcl-2 and Mcl-1.

Keywords
Bcl-2/Mcl-1; Dual inhibitor; Structure-based rational design.
Products